PANCREATIC ENZYME LEVELS IN DUODENAL FLUID OF CP PATIENTS - EURAND PEP

CP 患者十二指肠液中的胰酶水平 - EURAND PEP

• 批准号: 7717136
• 负责人: Phillip TOSKES
• 金额: $ 8.13万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717136
• 关键词: Abdominal Pain; Amylases; Biological Assay; Cholecystokinin; Computer Retrieval of Information on Scientific Projects Database; Duodenum; Endopeptidases; Evaluation; Excretory function; Exocrine pancreatic insufficiency; Fasting; Fatty acid glycerol esters; Feedback; Funding; Grant; Institution; Intestines; Laboratories; Lipase; Liquid substance; Malabsorption Syndromes; Methodology; Pancreas; Pancreatic enzyme; Patients; Peptide Hydrolases; Peptides; Preparation; Research; Research Personnel; Resources; Source; Techniques; United States National Institutes of Health; Upper arm; chronic pancreatitis; expectation; feeding; pancreatic juice

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ultimate expectation of this study and of the continued studies of feedback inhibition of pancreatic secretion in our laboratory is to develop a potent pancreatic enzyme preparation which can release its compounds consistently into the duodenum. Delivery of pancreatic lipase, amylase and total protease will be evaluated utilizing a intestinal aspiration methodology that this laboratory has utilized successfully on numerous occasions. Thirty subjects with chronic pancreatitis will be studied, fifteen of whom will have excretion of elevated amounts of fecal fat pancreatic insufficiency and fifteen with abdominal pain but who have not yet developed insufficiency. The delivery of lipase, amylase and total protease will be compared in a fasted and fed state with and without the addition of pancreatic enzymes. The levels of CCK and CCK releasing peptide will be collected and assayed in each arm of the study. This study will demonstrate the efficacy of the Eurand Pancreatic Enzyme Product PEP. This technique is a necessity for the evaluation of all pancreatic enzyme preparations whether it is for the treatment of fat malabsorption or abdominal pain.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究和我们实验室对胰腺分泌反馈抑制的持续研究的最终期望是开发一种有效的胰酶制剂，该制剂可以持续释放其化合物进入十二指肠。 胰脂肪酶、淀粉酶和总蛋白酶的递送将使用本实验室已多次成功使用的肠道抽吸方法进行评价。 将研究30例慢性胰腺炎受试者，其中15例将出现粪便脂肪排泄量升高的胰腺功能不全，15例伴有腹痛但尚未出现功能不全。 将在禁食和进食状态下比较添加和不添加胰酶的脂肪酶、淀粉酶和总蛋白酶的递送。 将在研究的每个组中收集并测定CCK和CCK释放肽的水平。本研究将证明Eurand胰酶产品PEP的有效性。 该技术是评价所有胰酶制剂的必要条件，无论是用于治疗脂肪吸收不良还是腹痛。